🧫
sEV angiogenic capability evaluation in metabolic disease patients
active
experiment
Created: 2026-04-06T12:31:46
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-b9e31d94-4962-4c12-b782-b6048dc7371f
🧫 Experiment Protocol
Exploratorytype 2 diabetes mellitus, obesity, ischemic diseasehuman patients, in vitro angiogenesis assays, in vivo angiogenesis modelsproposed
This experiment evaluated the angiogenic properties of serum-derived extracellular vesicles (sEV) isolated from different patient populations including type 2 diabetic subjects, obese individuals with and without diabetes, and subjects with ischemic disease. The study aimed to identify patients who may benefit from autologous sEV administration for pro-angiogenic therapeutic purposes. sEV were isolated from serum samples and their angiogenic capabilities were assessed both in vitro and in vivo using appropriate angiogenesis assays. The results showed that sEV display different angiogenic properties across these patient populations, with particular differences noted in type 2 diabetic patients.
PRIMARY OUTCOME
sEV angiogenic capability
EXPECTED OUTCOMES
Different angiogenic properties of sEV from different patient populations
SUCCESS CRITERIA
Measurable differences in angiogenic capability between patient groups
PROTOCOL
sEV isolation from serum samples, in vitro and in vivo angiogenesis assays across different patient populations
Source: PMID 31959759 ↗
🧫 Experiment Extras
PATHWAY
angiogenesis pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.